"""
Question: 1101 

Evidence: Data described in this brief report were obtained as part of a pilot study to assess the effectiveness and feasibility of implementing at-birth point of care infant HIV testing at 4 Kenyan government hospitals. Sequences were submitted to the Genbank under accession numbers MZ295233-MZ295242.

Rationale: The study presents new sequencing data generated specifically for this pilot project and provides new GenBank accession numbers, indicating the data were not previously published.

Answer: Yes
"""

"""
Question: 1102 

Evidence: RNA was extracted from the samples and the partial pol gene (protease, PR: codons 6--99; reverse transcriptase, RT: codons 1--251) of the amplified polymerase chain reaction products of HIV-1 were sequenced on the ABI PRISM 3130 xl Genetic Analyzer. The sequences were screened for HIVDR mutations using the Stanford HIV Sequence Database. Sequences were submitted to the Genbank under accession numbers MZ295233-MZ295242.

Rationale: The methods explicitly state that HIV-1 pol gene regions were sequenced and submitted to GenBank, confirming that HIV sequences were reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: RNA was extracted from the samples and the partial pol gene (protease, PR: codons 6--99; reverse transcriptase, RT: codons 1--251) of the amplified polymerase chain reaction products of HIV-1 were sequenced. We did no additional testing beyond that described in the study, thus cannot definitively state whether infant mutations were acquired through exposure to the drug or transmitted via the mother.

Rationale: The paper describes only direct sequencing of clinical samples and explicitly notes that no additional testing beyond described methods was performed; there is no mention of in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: The sequences were screened for HIVDR mutations using the Stanford HIV Sequence Database. We did no additional testing beyond that described in the study.

Rationale: Resistance was inferred genotypically using a database; there is no report of laboratory phenotypic susceptibility testing or in vitro IC measurements.

Answer: No
"""

"""
Question: 2101 

Evidence: Sequences were submitted to the Genbank under accession numbers MZ295233-MZ295242.

Rationale: The paper explicitly provides GenBank accession numbers for the sequences.

Answer: Yes
"""

"""
Question: 2102 

Evidence: Eligible mother-infant pairs included mothers (>18 years) living with HIV who presented for antenatal or maternal and child health services... Blood samples from participating mother-infant pairs were collected... Sequences were submitted to the Genbank under accession numbers MZ295233-MZ295242.

Rationale: The sequences are from clinical mother–infant samples rather than laboratory isolates, and they have associated GenBank accession numbers.

Answer: Yes
"""

"""
Question: 2103 

Evidence: Sequences were submitted to the Genbank under accession numbers MZ295233-MZ295242.

Rationale: The accession number range is explicitly provided in the text.

Answer: MZ295233–MZ295242
"""

"""
Question: 2202 

Evidence: Results and interpretation of the HIVDR analyses from the pairs with HIV drug resistance mutations are shown in Table 2. Infant 4: V179E, Y181C. Maternal 5: D67D/N, K70K/R, K219K/Q, M184V; K101E, G190A.

Rationale: Table 2 lists specific mutations for individual mothers and infants, demonstrating per-sample mutation lists.

Answer: Yes
"""

"""
Question: 2301 

Evidence: RNA was extracted from the samples and the partial pol gene ... of HIV-1 were sequenced.

Rationale: The methods specify that HIV-1 sequences were generated.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Pairs 1 (HIV subtype C) and 3 (HIV subtype A) had no HIV drug resistance mutations. HIV subtype: Pair 2 B, Pair 4 C, Pair 5 A.

Rationale: The text and Table 2 report subtypes A, B, and C among the sequenced viruses.

Answer: A, B, C
"""

"""
Question: 2303 

Evidence: RNA was extracted from the samples and the partial pol gene (protease, PR: codons 6--99; reverse transcriptase, RT: codons 1--251) ... were sequenced.

Rationale: The sequenced regions are specified as parts of the pol gene: protease and reverse transcriptase.

Answer: pol (protease and reverse transcriptase)
"""

"""
Question: 2304 

Evidence: RNA was extracted from the samples and the partial pol gene ... were sequenced. The sequences were screened for HIVDR mutations using the Stanford HIV Sequence Database.

Rationale: The study generated and analyzed HIV pol sequences.

Answer: Yes
"""

"""
Question: 2401 

Evidence: Expansion of prevention of mother-to-child transmission of HIV (PMTCT) programs in Kenya... Data described in this brief report were obtained as part of a pilot study ... at 4 Kenyan government hospitals.

Rationale: The setting and sample origin are in Kenya.

Answer: Kenya
"""

"""
Question: 2402 

Evidence: Eligible mother-infant pairs ... at one of the study hospitals between September 2017 and April 2018. Blood samples from participating mother-infant pairs were collected...

Rationale: Enrollment and sampling occurred within September 2017 to April 2018.

Answer: 2017–2018
"""

"""
Question: 2502 

Evidence: RNA was extracted ... and ... were sequenced on the ABI PRISM 3130 xl Genetic Analyzer using a Center for Disease Control-validated in-house genotyping assay. Due to the low sensitivity of the Sanger method of sequencing, some mutations may have been missed.

Rationale: The ABI 3130xl is a capillary Sanger sequencer and the text explicitly references Sanger sequencing.

Answer: Yes
"""

"""
Question: 2503 

Evidence: Due to the low sensitivity of the Sanger method of sequencing, some mutations may have been missed. RNA was extracted ... and ... were sequenced on the ABI PRISM 3130 xl Genetic Analyzer.

Rationale: The study used Sanger sequencing, and there is no mention of any next-generation sequencing technology.

Answer: No
"""

"""
Question: 2504 

Evidence: RNA was extracted from the samples and the partial pol gene ... were sequenced. We did no additional testing beyond that described in the study.

Rationale: The methods do not mention cloning prior to sequencing; only direct sequencing of amplified products is described.

Answer: NA
"""

"""
Question: 2505 

Evidence: RNA was extracted from the samples and the partial pol gene ... were sequenced. We did no additional testing beyond that described in the study.

Rationale: There is no mention of single-genome sequencing; the approach described is bulk PCR product sequencing.

Answer: NA
"""

"""
Question: 2506 

Evidence: RNA was extracted from the samples and the partial pol gene ... were sequenced. We did no additional testing beyond that described in the study.

Rationale: The paper does not describe molecular cloning of viral genomes; only direct sequencing is described.

Answer: NA
"""

"""
Question: 2601 

Evidence: Blood samples ... were collected ... separated into plasma and frozen. RNA was extracted from the samples and the partial pol gene ... were sequenced.

Rationale: Samples were processed to plasma and RNA (from plasma) was sequenced, indicating plasma HIV sequencing.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Blood samples ... were collected ... separated into plasma and frozen. RNA was extracted from the samples and the partial pol gene ... were sequenced.

Rationale: The paper describes plasma processing and RNA sequencing; there is no mention of PBMC DNA/RNA sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: ...resulting in a total of 5 mother-infant pairs being included in this brief report. Sequences were submitted to the Genbank under accession numbers MZ295233-MZ295242.

Rationale: Five pairs imply 10 individuals (mother + infant). Ten GenBank accessions corroborate sequencing of 10 plasma samples.

Answer: 10
"""

"""
Question: 2604 

Evidence: Blood samples ... were ... separated into plasma and frozen. RNA was extracted from the samples and the partial pol gene ... were sequenced.

Rationale: Only plasma sequencing is described; no PBMC sequencing was reported.

Answer: 0
"""

"""
Question: 2605 

Evidence: Blood samples ... were ... separated into plasma and frozen. RNA was extracted from the samples and the partial pol gene ... were sequenced.

Rationale: Sequencing of plasma RNA captures circulating, replicating virus rather than integrated provirus, indicating active replication sources.

Answer: Yes
"""

"""
Question: 2606 

Evidence: Blood samples ... were ... separated into plasma and frozen. RNA was extracted from the samples and the partial pol gene ... were sequenced.

Rationale: The study sequenced plasma RNA rather than proviral DNA from cells; therefore, it did not analyze the proviral DNA reservoir.

Answer: No
"""

"""
Question: 2701 

Evidence: The presence and type of HIV drug resistance mutations among 5 infants diagnosed with HIV were assessed and compared with their mothers’ viral mutations. Blood samples from participating mother-infant pairs were collected...

Rationale: The study explicitly includes infants and their mothers.

Answer: Yes
"""

"""
Question: 2702 

Evidence: Data described in this brief report were obtained as part of a pilot study to assess the effectiveness and feasibility of implementing at-birth point of care infant HIV testing at 4 Kenyan government hospitals. Eligible mother-infant pairs included mothers (>18 years) living with HIV who presented for antenatal or maternal and child health services...

Rationale: The description indicates an implementation pilot/observational study within routine services, not a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: Data described in this brief report were obtained as part of a pilot study to assess the effectiveness and feasibility of implementing at-birth point of care infant HIV testing at 4 Kenyan government hospitals. Eligible mother-infant pairs included mothers (>18 years) living with HIV who presented for antenatal or maternal and child health services...

Rationale: Since it is not a clinical trial, it follows that not all individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: ...resulting in a total of 5 mother-infant pairs being included in this brief report. Maternal and infant HIVDR samples were taken the same day...

Rationale: Five pairs mean 10 individuals, and both mothers and infants had samples taken for sequencing.

Answer: 10
"""

"""
Question: 3102 

Evidence: Maternal and infant HIVDR samples were taken the same day. Sequences were submitted to the Genbank under accession numbers MZ295233-MZ295242.

Rationale: Samples from all 10 individuals were sequenced and submitted to GenBank.

Answer: Yes
"""

"""
Question: 4101 

Evidence: Maternal and infant data [age, timing of maternal antiretroviral therapy (ART) initiation, ART regimen, ... infant prophylactic regimen...] were collected from clinical registers. Infant prophylactic regimen ... were collected.

Rationale: The paper does not explicitly state whether any sequenced individuals were ART-naive at the time of sampling; infants had varying prophylaxis and maternal ART was ongoing, leaving ART-naive status indeterminate.

Answer: NA
"""

"""
Question: 4102 

Evidence: Maternal ART regimen at study enrollment: 3TC+TDF+EFV; 3TC+TDF+EFV; 3TC+TDF+EFV; 3TC+AZT+NVP; 3TC+TDF+NVP. Timing of maternal ART initiation: Newly ... or Previously ...

Rationale: Mothers were receiving ART regimens (NNRTI-based) at enrollment, indicating sequences from ARV-experienced individuals.

Answer: Yes
"""

"""
Question: 4103 

Evidence: Maternal ART regimen at study enrollment ... Infant prophylactic regimen ... were collected. The paper does not explicitly state infant ART treatment status at sequencing.

Rationale: Although mothers were ART-experienced, ART-naive status for any participants is not clearly reported; therefore it is unclear if both naive and experienced groups are represented.

Answer: NA
"""

"""
Question: 4104 

Evidence: Maternal and infant data ... Infant prophylactic regimen ... were collected. The paper does not explicitly state infant ART treatment status at sequencing.

Rationale: The number of ART-naive individuals cannot be determined from the provided information.

Answer: NA
"""

"""
Question: 4105 

Evidence: Maternal and infant data [age, timing of maternal antiretroviral therapy (ART) initiation, ART regimen, ... infant prophylactic regimen...] were collected from clinical registers. Our measure of ART adherence was limited to the qualitative assessment (good, fair, poor) recorded by clinicians in standard clinical records.

Rationale: Although some treatment details were collected, the study does not provide a complete ART history for all individuals (e.g., full prior regimens, infant ART beyond prophylaxis), and even adherence data were limited.

Answer: No
"""

"""
Question: 4201 

Evidence: Most of the identified infant mutations matched their mother’s. The age of the infants at HIV diagnosis and the timing of collection of samples for HIVDR testing suggests that the HIV drug resistance mutations in the infants were more likely transmitted from the mother to the child than acquired.

Rationale: The study discusses likely transmission in a small sample but does not report prevalence estimates of transmitted resistance in a defined population.

Answer: No
"""

"""
Question: 4202 

Evidence: We found a high level of HIVDR mutations, with 3 of 5 (60%) mother-infant pairs harboring HIVDR mutations to at least 1 class of antiretroviral (ARV) medication. The study does not report pretreatment status at sequencing for all individuals.

Rationale: The paper does not present prevalence of pretreatment HIV drug resistance; it reports resistance findings in a small sequenced sample without pretreatment prevalence metrics.

Answer: No
"""

"""
Question: 4301 

Evidence: Maternal ART regimen at study enrollment: 3TC+TDF+EFV; 3TC+TDF+EFV; 3TC+TDF+EFV; 3TC+AZT+NVP; 3TC+TDF+NVP. Infant prophylactic regimen: AZT+NVP; ... NVP.

Rationale: The regimens include NRTIs (3TC, TDF, AZT) and NNRTIs (EFV, NVP), indicating these drug classes were received.

Answer: NRTIs and NNRTIs
"""

"""
Question: 4302 

Evidence: Maternal ART regimen at study enrollment ... lists only EFV or NVP with NRTIs. The recent shift to using dolutegravir ... as part of the first-line ART regimen ... may help mitigate these challenges.

Rationale: No integrase inhibitors were reported as received by participants; DTG is mentioned only as a broader programmatic shift.

Answer: No
"""

"""
Question: 4303 

Evidence: Maternal ART regimen at study enrollment: 3TC+TDF+EFV; ... 3TC+AZT+NVP; 3TC+TDF+NVP. Infant first-line regimens discussed in Table 2 are presented as guidelines at the time of study implementation.

Rationale: Reported received regimens do not include protease inhibitors; PI drugs are referenced only in guideline-based interpretations.

Answer: No
"""

"""
Question: 4304 

Evidence: Maternal ART regimen at study enrollment: 3TC+TDF+EFV; ... 3TC+AZT+NVP; 3TC+TDF+NVP. 

Rationale: Different mothers were on different ART combinations, indicating not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: Maternal ART regimen at study enrollment lists only EFV or NVP with NRTIs; no INSTIs are listed. The recent shift to using dolutegravir ... may help mitigate these challenges.

Rationale: Since no participant regimens included INSTIs, the individuals are considered INSTI-naive.

Answer: Yes
"""

"""
Question: 4403 

Evidence: Maternal ART regimen at study enrollment ... The paper does not report prior regimen switches for individuals.

Rationale: The number of individuals with more than one regimen over time is not provided.

Answer: NA
"""

"""
Question: 4404 

Evidence: Maternal ART regimen at study enrollment ... The paper does not report prior regimen switches for individuals.

Rationale: There is no information on individuals receiving more than two regimens.

Answer: NA
"""

"""
Question: 4405 

Evidence: Maternal ART regimen at study enrollment ... The paper does not report prior regimen switches for individuals.

Rationale: Without longitudinal regimen histories, it is not possible to determine if all individuals received the same number of regimens.

Answer: NA
"""

"""
Question: 4406 

Evidence: Maternal ART regimen at study enrollment ... The paper does not report prior regimen switches for individuals.

Rationale: The study provides only the regimen at enrollment, so it cannot establish whether all individuals received exactly one regimen overall.

Answer: NA
"""

"""
Question: 4501 

Evidence: Maternal ART regimen at study enrollment ... includes EFV or NVP-based regimens; no INSTIs are listed. The recent shift to using dolutegravir ... may help mitigate these challenges.

Rationale: Dolutegravir is discussed as a policy shift, not as a drug given to participants; no participant is reported as having received DTG.

Answer: 0
"""

"""
Question: 4502 

Evidence: Maternal ART regimen at study enrollment ... includes EFV or NVP-based regimens. 

Rationale: There is no mention of darunavir use among participants.

Answer: 0
"""

"""
Question: 5101 

Evidence: Maternal and infant HIVDR mutations were found in 3 (60%) of the 5 pairs. Results and interpretation of the HIVDR analyses from the pairs with HIV drug resistance mutations are shown in Table 2.

Rationale: Three pairs had resistance; from Table 2, the individuals with mutations are: Pair 2 mother (PI V82A), Pair 4 mother (NNRTI V179D) and infant (NNRTI V179E, Y181C), Pair 5 mother (NRTI D67D/N, K70K/R, K219K/Q, M184V; NNRTI K101E, G190A) and infant (NRTI D67N, K70R, K219Q). This totals 5 individuals.

Answer: 5
"""

"""
Question: 5102 

Evidence: RNA was extracted ... and the partial pol gene (protease ... reverse transcriptase ...) ... were sequenced. The sequences were screened for HIVDR mutations using the Stanford HIV Sequence Database.

Rationale: Only PR and RT regions were sequenced; integrase was not sequenced, so no INSTI-resistance mutations were reported.

Answer: 0
"""

"""
Question: 5103 

Evidence: Results and interpretation of the HIVDR analyses from the pairs with HIV drug resistance mutations are shown in Table 2. The sequences were screened for HIVDR mutations using the Stanford HIV Sequence Database.

Rationale: Although specific NRTI mutations are listed, the paper does not explicitly classify mutations as “TDF-resistance mutations,” and only clinical implication summaries are provided; therefore the exact count of individuals with TDF-resistance mutations cannot be determined with certainty from the text alone.

Answer: NA
"""

"""
Question: 5104 

Evidence: RNA was extracted ... and the partial pol gene (protease ... reverse transcriptase ...) ... were sequenced. 

Rationale: The integrase gene was not sequenced; therefore, no INSTI-resistance mutations were reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: The sequences were screened for HIVDR mutations using the Stanford HIV Sequence Database. We did no additional testing beyond that described in the study.

Rationale: No phenotypic susceptibility testing method was used or described.

Answer: NA
"""

"""
Question: 6102 

Evidence: The sequences were screened for HIVDR mutations using the Stanford HIV Sequence Database. We did no additional testing beyond that described in the study.

Rationale: The paper does not report IC50 or IC90 values.

Answer: No
"""

"""
Question: 6103 

Evidence: The sequences were screened for HIVDR mutations using the Stanford HIV Sequence Database. 

Rationale: There are no IC50 fold-change data; only genotypic interpretation is reported.

Answer: No
"""

"""
Question: 6104 

Evidence: The sequences were screened for HIVDR mutations using the Stanford HIV Sequence Database. We did no additional testing beyond that described in the study.

Rationale: No phenotypic assay was performed or named.

Answer: NA
"""

"""
Question: 6105 

Evidence: We did no additional testing beyond that described in the study. 

Rationale: Replication capacity data were not reported.

Answer: No
"""

"""
Question: 6106 

Evidence: The sequences were screened for HIVDR mutations using the Stanford HIV Sequence Database. 

Rationale: No phenotypic susceptibility testing or drug panel was performed; thus, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: RNA was extracted from the samples and the partial pol gene ... were sequenced. We did no additional testing beyond that described in the study.

Rationale: The study sequenced patient-derived viruses and did not construct site-directed mutants.

Answer: No
"""

"""
Question: 7102 

Evidence: RNA was extracted from the samples and the partial pol gene ... were sequenced. We did no additional testing beyond that described in the study.

Rationale: There is no mention of in vitro passage; only direct sequencing of clinical samples was performed.

Answer: No
"""